Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board

Research output: Contribution to journalShort surveypeer-review


Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalTrends in Immunology
Issue number2
Publication statusPublished - Feb 1 2019

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board'. Together they form a unique fingerprint.

Cite this